Mkts

Arbutus Biopharma Corporation

NASDAQ: ABUS
$4.02-0.05 (-1.23%)
As of Nov 20, 4:00 PM ET

Key statistics

Day range
3.974.09
52-week range
3.505.45
Today
Open4.01
Previous close4.02
Volume4.54M
Valuation
Market cap617.00M
P/E ratio4.03×
EPS (TTM)0.78
Income & risk
Dividend / yield—
Beta0.75
Avg volume4.12M
Discussion

ABUS News

Stories mentioning ABUS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue179,1261,051529.0010,7391,7641,5741,3391,726
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development4,1205,0065,7785,4988,9598,81014,27315,551
Sales General & Admin
Total Operating Expenses10,2186,3419,1889,25127,46315,50722,77923,309
Operating Income (Loss)168,908(5,290)(8,659)1,488(25,699)(13,933)(21,440)(21,583)
Interest Income815.00877.00952.001,0421,1971,4641,7471,829
Interest Expense34.00
Other Expense
Pretax Income
Tax Provision0.00
Net Income (Loss)169,695(3,756)(7,742)2,523(24,526)(12,532)(19,717)(19,796)
Earnings Per Share (Basic)0.88(0.02)(0.04)0.01(0.13)(0.07)(0.10)(0.11)
Earnings Per Share (Diluted)0.87(0.02)(0.04)0.01(0.13)(0.07)(0.10)(0.11)
Weighted Average Shares Outstanding (Basic)193,769191,600191,779191,551190,707185,609188,997188,041
Weighted Average Shares Outstanding (Diluted)195,214191,600191,779192,400190,707185,609188,997188,041

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About ABUS

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a stock listed on the Nasdaq Stock Market under the ticker symbol ABUS. It last traded at $4.02 (Nov 20, 2026, 4:00 PM ET), down 1.2% on the day. That gives Arbutus Biopharma a market capitalisation of $617.0M and a price-to-earnings ratio of 4.0.

Over the past 52 weeks ABUS has traded between $3.50 and $5.45.

Revenue for the quarter ended Mar 31, 2026 was $179.1M; net income $169.7M. Revenue was up 10055% from $1.8M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$179.1M$169.7M94.7%
Dec 31, 2025$1.1M-$3.8M-357.4%
Sep 30, 2025$529.0K-$7.7M-1463.5%
Jun 30, 2025$10.7M$2.5M23.5%

From Arbutus Biopharma’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…